Prior to joining Applied BioMath, Alison had an extensive modeling and simulation career at Pfizer, Inc., beginning in Sandwich, UK in 1994. In 2007, she transferred to the translational research group in Groton, CT. Most recently, she was a member of the translational modeling and simulation group in the biomedicines design department in Cambridge, MA, where she was the translational modeling and simulation lead supporting the oncology research unit.

During her career at Pfizer, Inc. Alison supported many research units including pain, cardiovascular, antibacterials, inflammation and immunology, immuno-oncology, and oncology to establish the use of modeling and translational pharmacology to drive projects and increase efficiency and effectiveness in achieving portfolio goals. In these roles she provided modeling and simulation support to small and large molecule therapeutics at different stages of research and development. Alison specializes in modeling and simulation of novel biotherapeutic drugs, including antibody drug conjugates, bispecific biologics, T-cell engagers, in order to understand complex mechanisms, validate targets, and translate to the clinic.

Alison graduated from St. Andrews University, Scotland, UK with a first-class honors degree in biochemistry. She is completing her PhD studies at the University of Leiden, The Netherlands on 'QSP modeling of biotherapeutic drugs in oncology.'


Key Research

  • Quantitative modeling predicts competitive advantages of a next generation anti‐NKG2A therapy over monalizumab for the treatment of cancer
  • Mechanistic Quantitative Pharmacology Strategies for the Early Clinical Development of Bispecific Antibodies in Oncology

Interested in speaking with an expert?

We'll put you in touch with the right person on our team. 

Schedule Brief Consultation